PAM

Peptidyl-glycine alpha-amidating monooxygenase

44,953 patent compounds predicted against PAM, 30,534 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL126976	0.69	3/20
SCHEMBL94604	0.60	3/20
SCHEMBL179684	0.52	3/20
SCHEMBL162936	0.50	3/20
SCHEMBL75506	0.38	3/20
SCHEMBL156767	1.00	2/20
SCHEMBL454	0.67	2/20
SCHEMBL1585	0.67	2/20
SCHEMBL5533	0.67	2/20
SCHEMBL8538	0.67	2/20
SCHEMBL24287	0.67	2/20
SCHEMBL25276	0.67	2/20
Glycol Distearate (SCHEMBL29407)	0.67	2/20
SCHEMBL102577	0.67	2/20
Ethyl Tetradecanoate (SCHEMBL116495)	0.67	2/20
SCHEMBL116995	0.67	2/20
SCHEMBL120620	0.67	2/20
SCHEMBL137195	0.67	2/20
SCHEMBL16463	0.66	2/20
Acetic Acid (SCHEMBL87739)	0.66	2/20

Germline variants in PAM on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PAM gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PAM by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing	PHASE4	COMPLETED
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.	PHASE3	COMPLETED
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis	PHASE3	COMPLETED
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)	PHASE3	COMPLETED
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues	PHASE3	COMPLETED
L-Arginine in Pre-Eclampsia	PHASE3	COMPLETED
Triptorelin for Ovary Protection in Childhood Onset Lupus	PHASE2	COMPLETED
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia	PHASE1/PHASE2	RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s)	PHASE1/PHASE2	NOT_YET_RECRUITING
Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer	PHASE2	COMPLETED
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment	PHASE2	COMPLETED
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy	PHASE2	UNKNOWN
Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU	PHASE2	COMPLETED
Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma	PHASE2	COMPLETED
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine	PHASE1	WITHDRAWN
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers	PHASE1	COMPLETED
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)	PHASE1	COMPLETED
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease	PHASE1	COMPLETED
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer	PHASE1	COMPLETED
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects	PHASE1	COMPLETED
Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)	EARLY_PHASE1	WITHDRAWN
Accuracy of Detection of Methemoglobin With Pulse Oximetry	nan	COMPLETED
Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)	nan	RECRUITING
The Protrieve PROTECTOR Study	nan	COMPLETED
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load	nan	COMPLETED
The Recovery in Stroke Using PAP Study	nan	RECRUITING
Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease	nan	RECRUITING
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions	nan	RECRUITING
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PAM binder may also engage these)

Protein	Name	Similarity
P10731	—	1.000	P10731 →
P97467	—	1.000	P97467 →
P08478	—	0.999	P08478 →
P14925	—	0.998	P14925 →
O18016	—	0.996	O18016 →
Q28056	—	0.995	Q28056 →
P12890	—	0.994	P12890 →
P34822	—	0.993	P34822 →
O35312	—	0.993	O35312 →
Q9XTQ6	—	0.992	Q9XTQ6 →
Q94128	—	0.992	Q94128 →
O54861	—	0.992	O54861 →
O95393	—	0.991	O95393 →
Q8BSY0	—	0.991	Q8BSY0 →
Q6UX71	—	0.991	Q6UX71 →
Q8UWD9	—	0.991	Q8UWD9 →
P52194	—	0.991	P52194 →
E1C3U7	—	0.991	E1C3U7 →
A6H737	—	0.991	A6H737 →
SORT1	Sortilin	0.991	landscape →
Q98TB4	—	0.991	Q98TB4 →
P84903	—	0.991	P84903 →
Q5QQ55	—	0.990	Q5QQ55 →
Q8AXC7	—	0.990	Q8AXC7 →
STIM1	Stromal interaction molecule 1	0.990	landscape →
Q9WTR0	—	0.990	Q9WTR0 →
Q09499	—	0.990	Q09499 →
O42222	—	0.990	O42222 →
O64758	—	0.990	O64758 →
KDM5D	Lysine-specific demethylase 5D	0.989	landscape →